[These findings have paved the way for the clinical development of PARP inhibitors in breast tumours especially in patients with germline mutations in the BRCA1 and/or BRCA2, a population known to have deficient homologous recombination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
Gene-disease associations inferred from text-mining the literature.
DisGeNET evidence - LITERATURE